Scientists at Cedars-Sinai and Emulate are using patient-on-a-chip and organ-on-a-chip technology to develop personalised treatments for diseases such as Parkinson's, amyotrophic lateral sclerosis, or Crohn's, according to an article published in Cellular and Molecular Gastroenterology and Hepatology. The research is part of a larger effort by the two institutions to use patient-to-patient transplants on patients with rare diseases. It’s an approach to precision medicine aimed at boosting personalized care based on the patient’s genetic makeup and also disease variants. The scientists then expose the cells to treatments, enabling them to find the best one without causing harm.
Scientists at Cedars-Sinai and Emulate are using patient-on-a-chip and organ-on-a-chip technology to develop personalised treatments for diseases such as Parkinson's, amyotrophic lateral sclerosis, or Crohn's, according to an article published in Cellular and Molecular Gastroenterology and Hepatology. The research is part of a larger effort by the two institutions to use patient-to-patient transplants on patients with rare diseases. The scientists then expose the cells to treatments, enabling them to find the best one without causing harm.